Literature DB >> 14063924

OESTROGENIC ACTIVITY ASSOCIATED WITH NON-FEMINIZING OVARIAN TUMOURS AFTER THE MENOPAUSE.

B G WREN, J FRAMPTON.   

Abstract

Entities:  

Keywords:  CYSTADENOMA, PAPILLARY; ENDOMETRIUM; ESTROGENS; OVARIAN NEOPLASMS; PHARMACOLOGY; PHYSIOLOGY; VAGINAL SMEARS

Mesh：

Substances：

Year:  1963        PMID： 14063924      PMCID： PMC1872973          DOI： 10.1136/bmj.2.5361.842

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  8 in total

1.  Preliminary observations on urinary oestrogen excretion in certain gynaecological disorders.

Authors:  J B BROWN; R KELLAR; G D MATTHEW
Journal:  J Obstet Gynaecol Br Emp       Date:  1959-04

2.  Relation of ovarian stromal hyperplasia to endometrial carcinoma.

Authors:  J W RODDICK; R R GREENE
Journal:  Am J Obstet Gynecol       Date:  1957-04       Impact factor: 8.661

3.  Post-menopausal oestrogen production.

Authors:  R A STRUTHERS
Journal:  Br Med J       Date:  1956-06-09

4.  Postmenopausal endometrial hyperplasia.

Authors:  E R NOVAK
Journal:  Am J Obstet Gynecol       Date:  1956-06       Impact factor: 8.661

5.  Ovarian function after the menopause.

Authors:  C L RANDALL; P K BIRTCH; J L HARKINS
Journal:  Am J Obstet Gynecol       Date:  1957-10       Impact factor: 8.661

6.  The normal post-menopausal endometrium.

Authors:  J M McBRIDE
Journal:  J Obstet Gynaecol Br Emp       Date:  1954-10

7.  Postmenopausal uterine bleeding.

Authors:  S L ISRAEL; L L WEBER
Journal:  Obstet Gynecol       Date:  1956-03       Impact factor: 7.661

8.  Hormonal assessment by vaginal cytology.

Authors:  E WACHTEL; J A PLESTER
Journal:  J Obstet Gynaecol Br Emp       Date:  1954-04
  8 in total
  1 in total

1.  Estrogen-producing endometrioid adenocarcinoma resembling sex cord-stromal tumor of the ovary: a review of four postmenopausal cases.

Authors:  Tomomi Katoh; Masanori Yasuda; Kosei Hasegawa; Eito Kozawa; Jun-ichi Maniwa; Hironobu Sasano
Journal:  Diagn Pathol       Date:  2012-11-28       Impact factor: 2.644
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.